The Latest Cardiac and Vascular News
January 21, 2025 10:10 AM Eastern Standard Time TEMPE, Ariz.–(BUSINESS WIRE)–Aptyx, a leading global developer and manufacturer of complex components and devices for the life sciences, today announced the acquisition of the Charlotte, North Carolina facility of Medical Murray, which develops and produces catheter-based interventional products and transcatheter implants. “This […]
[18F]florbetaben has been granted a Fast Track designation for cardiac amyloidosis, which will expedite the development of [18F]florbetaben for this indication [18F]florbetaben previously received orphan drug status as a diagnostic for the management of AL amyloidosis in EU and US The…
MIAMI, Jan. 21, 2025 /PRNewswire/ — The Amavita Foundation, a leading organization dedicated to advancing cardiovascular health and supporting patients facing chronic limb-threatening ischemia (CLTI), is pleased to announce the appointment of Patty Vila to its Board of Directors. A…
LINCOLN, Neb., Jan. 21, 2025 /PRNewswire/ — Neogen® Corporation (NASDAQ: NEOG), an innovative leader in food security solutions, announced today the launch of Igenity® BCHF to improve overall bovine heart health standards. Bovine Congestive Heart Failure (BCHF) stands as a significant…
– Plans for filing an IND was agreed with the FDA in a recent meeting –
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that AMBER-HFpEF (Assessment of CK-586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF) is open to enrollment. AMBER-HFpEF is a Phase 2 randomized, placebo-controlled, double-blind, multi-center, dose-finding clinical trial of CK-4021586 (CK-586) in patients with symptomatic heart failure with preserved ejection fraction (HFpEF) with left ventricular ejection fraction (LVEF) ≥60%. CK-586 is a cardiac myosin inhibitor in development for the potential treatment of a subgroup of with symptomatic HFpEF patients with hypercontractility and ventricular hypertrophy.
SEOUL, South Korea, Jan. 21, 2025 /PRNewswire/ — AIRS Medical has finalized a landmark agreement with Starvision, a leading radiological practice network in Germany, to bring its advanced MRI reconstruction technology, SwiftMR, to diagnostic imaging practices in Hannover and Munich. This…
TAMPA, Fla., Jan. 20, 2025 /PRNewswire/ — Concept Medical Inc. (CMI), a global leader in innovative drug-delivery technology across vascular interventions, proudly announces the successful completion of patient enrolment in the SirPAD Trial, with over 1,250 patients now enrolled. The…
LIVERMORE, Calif., Jan. 17, 2025 /PRNewswire/ — Advanced Bifurcation Systems Inc. (ABS), a leader in innovative solutions for bifurcation lesions in coronary angioplasty, announces the successful closure of a $20.8 million Simple Agreement for Future Equity (SAFE) financing round. The…
